Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.30
IMGN's Cash-to-Debt is ranked higher than
96% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. IMGN: 1.30 )
Ranked among companies with meaningful Cash-to-Debt only.
IMGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39  Med: No Debt Max: 50356.33
Current: 1.3
0.39
50356.33
Equity-to-Asset -1.03
IMGN's Equity-to-Asset is ranked lower than
96% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IMGN: -1.03 )
Ranked among companies with meaningful Equity-to-Asset only.
IMGN' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.03  Med: 0.74 Max: 0.96
Current: -1.03
-1.03
0.96
Piotroski F-Score: 1
Altman Z-Score: -8.65
Beneish M-Score: 34.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -210.62
IMGN's Operating Margin % is ranked lower than
62% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. IMGN: -210.62 )
Ranked among companies with meaningful Operating Margin % only.
IMGN' s Operating Margin % Range Over the Past 10 Years
Min: -447.86  Med: -162.45 Max: -58.16
Current: -210.62
-447.86
-58.16
Net Margin % -247.59
IMGN's Net Margin % is ranked lower than
65% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. IMGN: -247.59 )
Ranked among companies with meaningful Net Margin % only.
IMGN' s Net Margin % Range Over the Past 10 Years
Min: -448.24  Med: -162.03 Max: -49.69
Current: -247.59
-448.24
-49.69
ROA % -64.90
IMGN's ROA % is ranked lower than
77% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. IMGN: -64.90 )
Ranked among companies with meaningful ROA % only.
IMGN' s ROA % Range Over the Past 10 Years
Min: -64.9  Med: -36.91 Max: -21.76
Current: -64.9
-64.9
-21.76
ROC (Joel Greenblatt) % -722.56
IMGN's ROC (Joel Greenblatt) % is ranked lower than
55% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. IMGN: -722.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IMGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -722.56  Med: -383.13 Max: -150
Current: -722.56
-722.56
-150
3-Year Revenue Growth Rate 17.70
IMGN's 3-Year Revenue Growth Rate is ranked higher than
91% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. IMGN: 17.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IMGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -47.7  Med: 0.7 Max: 115.4
Current: 17.7
-47.7
115.4
3-Year EBITDA Growth Rate 19.10
IMGN's 3-Year EBITDA Growth Rate is ranked lower than
67% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. IMGN: 19.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IMGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -72.2  Med: 1 Max: 296.3
Current: 19.1
-72.2
296.3
3-Year EPS without NRI Growth Rate 24.30
IMGN's 3-Year EPS without NRI Growth Rate is ranked lower than
59% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. IMGN: 24.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IMGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -75.7  Med: 0 Max: 263.4
Current: 24.3
-75.7
263.4
GuruFocus has detected 6 Warning Signs with Immunogen Inc $IMGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IMGN's 30-Y Financials

Financials (Next Earnings Date: 2017-07-21 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

IMGN Guru Trades in Q2 2016

Jim Simons 1,967,140 sh (New)
Paul Tudor Jones 63,300 sh (New)
Ken Fisher 253,701 sh (+3.88%)
PRIMECAP Management 10,113,629 sh (-21.40%)
» More
Q3 2016

IMGN Guru Trades in Q3 2016

Jim Simons 2,503,340 sh (+27.26%)
Ken Fisher 253,701 sh (unchged)
PRIMECAP Management 9,619,122 sh (-4.89%)
Paul Tudor Jones 30,249 sh (-52.21%)
» More
Q4 2016

IMGN Guru Trades in Q4 2016

Paul Tudor Jones 32,880 sh (+8.70%)
Jim Simons 2,481,740 sh (-0.86%)
Ken Fisher 248,576 sh (-2.02%)
PRIMECAP Management 5,052,943 sh (-47.47%)
» More
Q1 2017

IMGN Guru Trades in Q1 2017

Ken Fisher 253,676 sh (+2.05%)
PRIMECAP Management 3,966,000 sh (-21.51%)
Paul Tudor Jones 24,493 sh (-25.51%)
Jim Simons 1,477,946 sh (-40.45%)
» More
» Details

Insider Trades

Latest Guru Trades with IMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ITCI, NAS:SPPI, NAS:MACK, NAS:BOLD, NAS:GERN, NAS:PGNX, NAS:ATRA, NAS:SYRS, NAS:BCRX, OTCPK:SXMDF, NAS:ADAP, OTCPK:SNBIF, NAS:ACIU, NAS:NLNK, OTCPK:ARGNF, OTCPK:SPHDF, NAS:NTLA, NAS:ARNA, NAS:MYOK, NAS:BLCM » details
Traded in other countries:IMU.Germany,
Headquarter Location:USA
Immunogen Inc is a clinical-stage biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products.

Immunogen is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.

Ratios

vs
industry
vs
history
PS Ratio 7.90
IMGN's PS Ratio is ranked higher than
63% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. IMGN: 7.90 )
Ranked among companies with meaningful PS Ratio only.
IMGN' s PS Ratio Range Over the Past 10 Years
Min: 2.67  Med: 14.92 Max: 97.63
Current: 7.9
2.67
97.63
EV-to-EBIT -3.58
IMGN's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. IMGN: -3.58 )
Ranked among companies with meaningful EV-to-EBIT only.
IMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -44  Med: -9.1 Max: 0.1
Current: -3.58
-44
0.1
EV-to-EBITDA -3.71
IMGN's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. IMGN: -3.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
IMGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -51.8  Med: -10.1 Max: 0.1
Current: -3.71
-51.8
0.1
Current Ratio 3.52
IMGN's Current Ratio is ranked lower than
99.99% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. IMGN: 3.52 )
Ranked among companies with meaningful Current Ratio only.
IMGN' s Current Ratio Range Over the Past 10 Years
Min: 0.51  Med: 7.34 Max: 60.86
Current: 3.52
0.51
60.86
Quick Ratio 3.44
IMGN's Quick Ratio is ranked lower than
99.99% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. IMGN: 3.44 )
Ranked among companies with meaningful Quick Ratio only.
IMGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.51  Med: 7.25 Max: 60.86
Current: 3.44
0.51
60.86
Days Sales Outstanding 24.75
IMGN's Days Sales Outstanding is ranked higher than
96% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. IMGN: 24.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
IMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.88  Med: 18.19 Max: 88.26
Current: 24.75
2.88
88.26

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
IMGN's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. IMGN: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -87.6  Med: -11.2 Max: -0.7
Current: -1
-87.6
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.52
IMGN's Price-to-Median-PS-Value is ranked higher than
80% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. IMGN: 0.52 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IMGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 2.14 Max: 10.53
Current: 0.52
0.22
10.53
Earnings Yield (Greenblatt) % -27.87
IMGN's Earnings Yield (Greenblatt) % is ranked lower than
96% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. IMGN: -27.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IMGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15095.13  Med: 0 Max: 10020.99
Current: -27.87
-15095.13
10020.99

More Statistics

Revenue (TTM) (Mil) $57.41
EPS (TTM) $ -1.63
Beta2.64
Short Percentage of Float17.94%
52-Week Range $1.51 - 6.21
Shares Outstanding (Mil)89.35

Analyst Estimate

Jun17 Jun18 Jun19 Jun20
Revenue (Mil $) 59 15 111 320
EPS ($) -1.14 -1.72 -0.87 0.77
EPS without NRI ($) -1.14 -1.72 -0.87 0.77
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IMGN

Headlines

Articles On GuruFocus.com
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
Gulf Resources (GURE) Soars on Natural Gas Discovery, ImmunoGen (IMGN) and Synaptics (SYNA) Surge on Jan 31 2015 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Murray Stahl’s $6.4 Billion Horizon Kinetics Sells Out Six Companies in First Quarter May 28 2013 
ImmunoGen Inc. Reports Operating Results (10-Q) Feb 08 2011 
ImmunoGen Inc. Reports Operating Results (10-Q) Oct 29 2010 
ImmunoGen Inc. Reports Operating Results (10-K) Aug 27 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Apr 30 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Jan 29 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
ImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher May 19 2017
Why ImmunoGen, Inc. Jumped Higher Today May 18 2017
ImmunoGen drug moving ahead in single-agent, combination trials May 17 2017
ImmunoGen Announces New Clinical Data with Mirvetuximab Soravtansine in Ovarian Cancer to be... May 17 2017
Why ImmunoGen, Inc. Stock Is Flying High Today May 15 2017
Edited Transcript of IMGN earnings conference call or presentation 5-May-17 12:00pm GMT May 11 2017
ImmunoGen, Inc. Begins FORWARD I, Investors Wait May 10 2017
ImmunoGen (IMGN) Posts Narrower-than-Expected Loss in Q1 May 08 2017
Today's Research Reports on Stocks to Watch: ImmunoGen and Ocular Therapeutix May 08 2017
ImmunoGen (IMGN) Reports Narrower-than-Expected Loss May 05 2017
Investor Network: ImmunoGen, Inc. to Host Earnings Call May 05 2017
ImmunoGen reports 1Q loss May 05 2017
ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results May 05 2017
Why ImmunoGen (IMGN) Might Surprise This Earnings Season May 04 2017
Here's Why ImmunoGen Rose 10.7% in April May 03 2017
Is ImmunoGen (IMGN) Poised for a Beat this Earnings Season? May 02 2017
ImmunoGen Announces Results from Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation... May 01 2017
When Will ImmunoGen, Inc. Finally Start Making Money? Apr 27 2017
ImmunoGen, Inc. – Value Analysis (NASDAQ:IMGN) : April 21, 2017 Apr 21 2017
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2017 Financial Results Apr 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat